OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

OKYO Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel small-molecule therapies that modulate the innate immune system. The firm focuses on targeting key pathways involved in inflammation and fibrosis, including the stimulator of interferon genes (STING) and caspase-1. By leveraging proprietary chemistry and translational biology capabilities, OKYO aims to deliver treatments for conditions with unmet medical needs, such as oral mucositis, metabolic dysfunction, and inflammatory skin diseases.

The company’s lead investigational drug, OK-101, is a first-in-class STING agonist currently in clinical trials for prevention and treatment of oral mucositis in cancer patients. Additional pipeline candidates include OK-201, a caspase-1 inhibitor in development for nonalcoholic fatty liver disease and insulin resistance, and OK-302, a preclinical program targeting atopic dermatitis. OKYO also pursues collaborations to explore complementary immuno-modulatory approaches and expand its therapeutic footprint in fibrotic and auto-inflammatory disorders.

Originally founded as Edesa Biotech, the company rebranded to OKYO Pharma in 2022 concurrent with its listing on the Nasdaq exchange. Headquartered in Cambridge, Massachusetts, OKYO maintains research and development operations in South Korea, enabling a global reach and access to diverse scientific talent. The firm’s history integrates a strong academic foundation with industry expertise to advance its small-molecule portfolio from discovery through clinical development.

OKYO Pharma is led by Chief Executive Officer Dr. Raymond Im, whose experience in immunology and translational research guides the company’s strategic direction. Supported by a leadership team with deep backgrounds in drug discovery, clinical development, and regulatory affairs, OKYO continues to build a robust pipeline aimed at delivering new treatment options for patients suffering from debilitating inflammatory and fibrotic diseases.

Key Stats

• Today's Range: $2.67 to $2.85
• 50-Day Range: $1.34 to $3.01
• 52-Week Range: $0.81 to $3.11
• Volume: 46,619 shs
• Average Volume: 156,176 shs
• Market Capitalization: $102.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 408th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

OKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OKYO Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for OKYO Pharma are expected to remain at ($0.17) per share in the coming year.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.51% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 34.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.51% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 34.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.28

News Sentiment

OKYO Pharma has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for OKYO Pharma this week, compared to 1 article on an average week.

Search Interest

2 people have searched for OKYO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.97% of the stock of OKYO Pharma is held by institutions.

OKYO Stock Analysis - Frequently Asked Questions

How have OKYO shares performed this year?

OKYO Pharma's stock was trading at $1.1499 at the beginning of the year. Since then, OKYO shares have increased by 137.4% and is now trading at $2.73.

When did OKYO Pharma IPO?

OKYO Pharma (OKYO) raised $2 million in an initial public offering (IPO) on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share.

Who are OKYO Pharma's major shareholders?

OKYO Pharma's top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.03%).
View institutional ownership trends.

How do I buy shares of OKYO Pharma?

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OKYO Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F).

Company Calendar

• Today: 7/23/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OKYO
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OKYO Pharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +154.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.20) per share
• Price / Book: -13.75

Miscellaneous

• Outstanding Shares: 37,610,000
• Free Float: 20,146,000
• Market Cap: $103.43 million
• Optionable: Not Optionable
• Beta: -0.09